371 related articles for article (PubMed ID: 24072665)
1. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
4. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
5. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.
Apostolidis A; Thompson C; Yan X; Mourad S
World J Urol; 2013 Dec; 31(6):1469-74. PubMed ID: 23160758
[TBL] [Abstract][Full Text] [Related]
6. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
Nitti V; Haag-Molkenteller C; Kennelly M; Chancellor M; Jenkins B; Schurch B
Medicine (Baltimore); 2023 Jul; 102(S1):e32377. PubMed ID: 37499088
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.
Kennelly M; Dmochowski R; Schulte-Baukloh H; Ethans K; Del Popolo G; Moore C; Jenkins B; Guard S; Zheng Y; Karsenty G;
Neurourol Urodyn; 2017 Feb; 36(2):368-375. PubMed ID: 26607743
[TBL] [Abstract][Full Text] [Related]
8. AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2).
Denys P; Castaño Botero JC; Vita Nunes RL; Wachs B; Mendes Gomes C; Krivoborodov G; Tu LM; Del-Popolo G; Thompson C; Vilain C; Volteau M; Kennelly M;
Neurourol Urodyn; 2023 Jan; 42(1):153-167. PubMed ID: 36321799
[TBL] [Abstract][Full Text] [Related]
9. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity.
Chartier-Kastler E; Rovner E; Hepp Z; Khalaf K; Ni Q; Chancellor M
Neurourol Urodyn; 2016 Jun; 35(5):595-600. PubMed ID: 25846869
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Honda M; Yokoyama O; Takahashi R; Matsuda T; Nakayama T; Mogi T
Int J Urol; 2021 Sep; 28(9):906-912. PubMed ID: 34075630
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity.
Chancellor MB; Patel V; Leng WW; Shenot PJ; Lam W; Globe DR; Loeb AL; Chapple CR
Neurology; 2013 Aug; 81(9):841-8. PubMed ID: 23892704
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2).
Kennelly M; Cruz F; Herschorn S; Abrams P; Onem K; Solomonov VK; Del Rosario Figueroa Coz E; Manu-Marin A; Giannantoni A; Thompson C; Vilain C; Volteau M; Denys P;
Eur Urol; 2022 Aug; 82(2):223-232. PubMed ID: 35400537
[TBL] [Abstract][Full Text] [Related]
15. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury.
Chen G; Liao L
Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094
[TBL] [Abstract][Full Text] [Related]
16. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.
Sievert KD; Chapple C; Herschorn S; Joshi M; Zhou J; Nardo C; Nitti VW
Int J Clin Pract; 2014 Oct; 68(10):1246-56. PubMed ID: 24754838
[TBL] [Abstract][Full Text] [Related]
18. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
19. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.
Krhut J; Samal V; Nemec D; Zvara P
Spinal Cord; 2012 Dec; 50(12):904-7. PubMed ID: 22801191
[TBL] [Abstract][Full Text] [Related]
20. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
